EMERGENCY EMERGENCY!!! DOUBLE ANTI-FUNGAL GUMMY!
Cantor reiterates Overweight ratings on anti-fungal stocks Cidara, Scynexis 17:58 CDTX, SCYX In a Large Cap Pharma, Biopharma, & Biotech note, Cantor Fitzgerald analyst Louise Chen reiterated Overweight ratings on two anti-fungal stocks, Cidara Therapeutics (CDTX) and Scynexis (SCYX), with target prices of $5 and $15, respectively. The research note follows the CDC issuing a press release that highlighted "the increasing threat of the spread of antimicrobial-resistant fungus in healthcare facilities." which Cantor sees as "concerning," and emphasized the need for a "new effective treatment." The analyst believes both companies have potential positive catalysts in this space within the next 12-18 months, highlighting Cidara's rezafungin and Scynexis' Ibrexafungerp.
CDTX-
CDTX Cidara Therapeutics, Inc.
$1.980.21(+11.86%)4:00 PM 03/21/23
NASDAQ |$USD |Pre-Market:$2.14+0.16(+8.08%)7:34 AM
SCYX-
SCYX SCYNEXIS, Inc.
$1.560.41(+35.65%)3:59 PM 03/21/23
NASDAQ |$USD |Pre-Market:$1.66+0.10(+6.41%)7:33 AM